Tissuegene-c induces long-term analgesic effects through modulation of pain mediators and neuronal sensitization in a monoiodoacetate-induced osteoarthritis pain rat model.

Purpose: TissueGene-C (TG-C), comprising human allogeneic chondrocytes and irradiated GP2-293 cells manipulated to overexpress transforming growth factor- β1 (TGF-β1), has been developed as a novel cell-based gene therapy for osteoarthritis (OA) drug. We aim to determine analgesic mechanism of TG-C in a pre-clinical animal model with MIA-induced pain.

Source: Osteoarthritis and Cartilage - April 29, 2023 Category: Rheumatology Authors: E. Park, J. Seo, Y. Lee, K. Park, K-r. Kim, H. Lee, S. Lee, S. Kim, A. Mobasheri, H. Choi Source Type: research